Sebti

Christophe Sebti, Cagnes Sur Mer FR

Patent application number

Description

Published

20080319866

METHOD AND SYSTEM TO HAND OVER AN ONLINE TRANSACTION TO A HELP DESK ASSISTANT - A method of providing assistance to an end-user of an online software application running from a web server. While the end-user and the web server communicate through at least one data network, during a web session initiated by the end-user from a client software application, the online software application provides a manner of requesting assistance from a help desk on at least one of the web page returned to the client application. When the end-user activates the manner of requesting assistance he/she obtains from the server of the online software application a keyword associated to the web session. End-user further obtains at least one telephone number of the help desk to call. When the end-user is calling the help desk through a telephone network the keyword is communicated to an assistant. After the assistant has successfully logged in to the web server the web session initiated by the end-user is shared with the assistant. Then, a transaction in progress with the online software application can be handed over to the assistant who will complete it on behalf of the end-user.

Growth Factor Binding Molecules - Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.

08-19-2010

20110124602

Stat3 Inhibitor Having Anti-Cancer Activity and Methods - A small-molecule Stat3 dimerization inhibitor, S3I-M2001, is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival genes, such as Bcl-xL. The disclosed compound is useful as a new potential treatment for certain cancers.

Thami Sebti, Brussels BE

Patent application number

Description

Published

20100119587

SOLID LIPIDIC PARTICLES AS PHARMACEUTICALLY ACCEPTABLE FILLERS OR CARRIERS FOR INHALATION - The present invention relates to new compositions of (active) solid lipidic particles (SLP), e.g. for inhalation, and their use as carriers or as fillers in pharmaceutical compositions. It also relates new formulations obtained by mixing a SLP composition of the invention and a (micronized) active compound. It further relates to a method for fabricating said compositions of (active) solid lipidic particles.

05-13-2010

Thami Sebti, Braine-Le-Comte BE

Patent application number

Description

Published

20150017244

DRY POWDER FORMULATION OF AZOLE DERIVATIVE FOR INHALATION - A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.